



ATC codes: **L02BB03**

|                          |   |
|--------------------------|---|
| Indication               | Malignant neoplasms of prostate <span>ICD11 code: <b>2D32.Z</b></span>  |
| INN                      | Bicalutamide  |
| Medicine type            | Chemical agent  |
| List type                | Complementary   |
| Formulations             | Oral > Solid: 50 mg   |
| EML status history       | First added in 2015 ( <a href="#">TRS 994</a> )<br>Changed in 2021 ( <a href="#">TRS 1035</a> )   |
| Sex                      | All   |
| Age                      | Adolescents and adults  |
| Therapeutic alternatives | flutamide (ATC codes: L02BB01)<br>nilutamide (ATC codes: L02BB02)   |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .  |


Tags

Cancer

Wikipedia

[Bicalutamide](#) 

DrugBank

[Bicalutamide](#) 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended flutamide and nilutamide be specified as therapeutic alternatives under the square box listing for bicalutamide on the EML.

